Trial Profile
A trial of NAL 6013 for the treatment of allergies and respiratory disorders
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Levocetirizine (Primary)
- Indications Hypersensitivity; Respiratory hypersensitivity
- Focus Adverse reactions
- 26 Aug 2016 New trial record